AlphAIAlphAI — Financial news for AI agents
fool.comSEP 142 min read$KVUE

Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now

Kenvue (KVUE) is highlighted as a strong high-yield dividend stock with a 4.68% yield and 64 years of consecutive dividend increases. Its stable of well-known brands reported Q2 revenue of $3.95B and EPS of $0.24. The company is being acquired by Kimberly-Clark (KMB), another Dividend King, which may create uncertainty about Kenvue's dividend.

Original reporting
fool.com
Published Sep 14, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 5:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now — source image
Source · fool.com
Decision brief

The 30-second read

$KVUENeutralMed
01

Why it matters

The merger could create a dominant consumer‑health player, affecting dividend yields and cost structures.

02

Market read

The announced acquisition is material for dividend‑focused investors and may move both stocks.

03

What to watch

Regulatory approval risk and potential antitrust scrutiny.

Relevance 8/10Novelty 7/10Timing: recent announcement

Background

Kenvue, spun off from Johnson & Johnson, is a Dividend King with a 4.68% yield. Kimberly-Clark, also a Dividend King, offers a higher yield.

Company-level read

Ticker impact

$KVUENeutralHigh confidence
Context

Kenvue is the target of an announced acquisition by Kimberly-Clark.

Expected impact

Potential upside if deal closes; downside risk if blocked.

Evidence & confidence

Acquisition creates uncertainty around dividend policy and may trigger a premium.

$KMBBullishHigh confidence
Context

Kimberly-Clark is the acquirer in the announced Kenvue deal.

Expected impact

Likely modest rally on deal completion expectations.

Evidence & confidence

Deal adds a dividend‑rich business, enhancing KMB's yield profile.

Market effects

Sector

Healthcare consumer segment may see consolidation pressure.

Regional

U.S. consumer health stocks could be re‑priced.

Global

Large‑cap dividend investors may adjust allocations.

Counterpoint

What could challenge this read

Deal could dilute Kenvue's dividend focus and introduce integration risk.

Key entities

  • Company
    Kenvue

    Consumer health company, Dividend King.

  • Company
    Kimberly-Clark

    Personal care products maker, Dividend King.

Read at source← All news

Related articles

SEP 14
$KMBMedAI 8/10

KMB Looks 18.8% Undervalued on GF Value™ Amid Dividend Concerns

Kimberly-Clark (KMB) shares rose 2.5% after announcing adjustments to address EU antitrust concerns over its $40B Kenvue (KVUE) acquisition. The EU decision deadline is September 29. KMB offers a 5.09% dividend yield but has a high payout ratio of 0.89, raising sustainability concerns. Its GF Value™ suggests the stock is 18.8% undervalued, with a GF Score™ of 72/100.

gurufocus.com2 min
SEP 14
$KVUEMedAI 9/10

Clark Eyes Asset Sales to Secure EU Nod for Kenvue Deal

Kimberly-Clark (KMB) is preparing asset sales to address EU antitrust concerns over its $40B acquisition of Kenvue (KVUE). The EU is expected to formally raise concerns this week. Shares of both companies rose on the news. The deal, announced last November, would expand Kimberly-Clark's product portfolio. The EU has until September 29 for a preliminary review.

globalbankingandfinance.com2 min
SEP 14
$KMBHighAI 9/10

Exclusive-Kimberly-Clark prepares asset sales to win EU nod for Kenvue deal, sources say

Kimberly-Clark is preparing asset sales to address EU antitrust concerns regarding its $40 billion acquisition of Kenvue. The European Commission is expected to formally raise its concerns this week. Kimberly-Clark shares rose 2.7% and Kenvue gained 2.3% on the news. The deal, announced in November, would expand Kimberly-Clark's product range to include Kenvue's brands like Listerine, Aveeno, and Neutrogena.

live.euronext.com2 min
SEP 14
$KMBHighAI 9/10

Health Giants Make Big Moves and Discoveries

Kimberly-Clark negotiates EU regulators for $40B Kenvue acquisition, offering concessions. Definium Therapeutics' LSD-based drug reduced anxiety in trials. Scholar Rock's SMA drug priced at $11,659 per vial. Electra Therapeutics targets $977.6M IPO valuation. BioNTech's lung cancer treatment shows trial success.

devdiscourse.com3 min
SEP 14
$KMBHighAI 9/10

Exclusive-Kimberly-Clark readies asset sales in bid for EU nod for Kenvue deal, sources say

Kimberly-Clark (KMB) is preparing asset sales to address EU antitrust concerns regarding its $40 billion acquisition of Kenvue. The EU is expected to formally raise its concerns this week, with Kimberly-Clark facing a September 29 deadline to submit concessions or face a full investigation. The deal has already received conditional approval in Australia and South Africa.

investing.com2 min